Nurix Earnings Reports

Nurix Therapeutics reported Q3 FY25 results with lower revenue and a larger net loss compared to the prior year, as the company increased spending to support the clinical advancement of its pipeline, including bexobrutideg.

Nurix significantly increased revenue due to milestone and license payments from collaborations with Sanofi and Gilead, while continuing to invest heavily in R&D as it advances key programs toward pivotal trials.

Nurix Therapeutics reported a strong first quarter for fiscal year 2025, with total revenue increasing to $18.5 million, primarily driven by collaboration milestones. The company also achieved significant regulatory and clinical milestones, including Orphan Drug Designation for bexobrutideg and key leadership appointments, while maintaining a strong cash position.

Nurix Therapeutics reported Q4 revenue of $13.3 million and a net loss of $58.5 million, or ($0.75) per share. The company's cash, cash equivalents, and marketable securities totaled $609.6 million as of November 30, 2024.

Nurix Therapeutics reported a net loss of $49.0 million, or ($0.67) per share, for the third quarter ended August 31, 2024. The company's cash, cash equivalents and marketable securities were $457.5 million as of August 31, 2024.

Nurix Therapeutics reported collaboration revenue of $12.1 million for the second quarter of fiscal year 2024, compared to $10.7 million for the same period in 2023. The net loss for the quarter was $44.5 million, or ($0.71) per share, compared to a net loss of $24.3 million, or ($0.45) per share, for the same quarter in the previous year. The company ended the quarter with $452.5 million in cash, cash equivalents and marketable securities.

Nurix Therapeutics reported revenue of $16.6 million for the first quarter of fiscal year 2024, compared to $12.7 million for the same period in the previous year. The net loss for the quarter was $41.5 million, or $0.76 per share, compared to a net loss of $40.7 million, or $0.75 per share, for the first quarter of fiscal year 2023.

Nurix Therapeutics reported an increase in revenue for both the three months and twelve months ended November 30, 2023, compared to the previous year. The company's net loss decreased for both the three-month and twelve-month periods. They maintained a strong financial position with cash and investments of $295.3 million.

Nurix Therapeutics reported revenue of $18.5 million and a net loss of $37.0 million for the third quarter of fiscal year 2023. The company highlighted a strategic collaboration with Seagen, resulting in a $60 million upfront payment, and maintained a strong financial position with cash runway into the second quarter of 2025.

Nurix Therapeutics reported revenue of $30.7 million for the quarter ended May 31, 2023, which included a $20 million licensing payment from Gilead. The net loss was $24.3 million, or ($0.45) per share. Cash, cash equivalents and marketable securities totaled $308.6 million as of May 31, 2023.

Nurix Therapeutics reported collaboration revenue of $12.7 million for the first quarter ended February 28, 2023. The company's net loss was $40.7 million, or ($0.75) per share. Cash, cash equivalents and marketable securities totaled $325.6 million as of February 28, 2023.

Nurix Therapeutics reported collaboration revenue of $6.8 million for the quarter and a net loss of $46.7 million, or ($0.87) per share. The company's cash, cash equivalents and marketable securities totaled $373.0 million as of November 30, 2022.

Nurix Therapeutics reported a net loss of $45.7 million for the third quarter ended August 31, 2022. The company's cash, cash equivalents, and marketable securities totaled $413.6 million as of August 31, 2022. They also completed two registered direct offerings in July raising gross proceeds of $95 million.

Nurix Therapeutics reported collaboration revenue of $11.4 million for the second quarter of 2022, compared to $7.1 million for the same period in 2021. The net loss for the quarter was $45.4 million, or ($1.01) per share, compared to a net loss of $26.4 million, or ($0.60) per share for the same period in 2021. The company's cash, cash equivalents, and investments totaled $348.8 million as of May 31, 2022.

Nurix Therapeutics reported collaboration revenue of $9.6 million for the first quarter ended February 28, 2022. The company's net loss was $42.5 million, or ($0.95) per share. As of February 28, 2022, Nurix had cash, cash equivalents and investments of $385.7 million.

Nurix Therapeutics reported a net loss of $37.7 million, or $0.85 per share, for the fourth quarter ended November 30, 2021. The company's collaboration revenue was $7.4 million, and research and development expenses were $36.5 million. Nurix ended the year with $432.9 million in cash, cash equivalents and investments.

Nurix Therapeutics reported collaboration revenue of $10.3 million and a net loss of $28.8 million, or ($0.65) per share for the third quarter ended August 31, 2021. The company's cash, cash equivalents and investments totaled $465.4 million as of August 31, 2021.

Nurix Therapeutics reported collaboration revenue of $5.0 million for the first quarter of 2021, compared to $2.9 million for the same period in 2020. The net loss was $24.3 million, or ($0.63) per share. The company's cash, cash equivalents, and investments totaled $380.3 million as of February 28, 2021, and $530.4 million proforma including net proceeds from follow-on offering.

Nurix Therapeutics reported collaboration revenue of $6.7 million for the fourth quarter of 2020, with a net loss of $19.9 million, or $0.51 per share. The company's cash, cash equivalents, and investments totaled $372.0 million as of November 30, 2020.

Nurix Therapeutics reported a collaboration revenue of $4.1 million for the third quarter of 2020, compared to $10.6 million for the same period in 2019. The company's net loss was $18.5 million, or ($0.59) per share, compared to a net loss of $2.4 million, or ($0.66) per share, for the same period in 2019. As of August 31, 2020, the company had cash, cash equivalents and investments of $395.1 million compared to $38.2 million as of November 30, 2019.